The shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
promises to change the nature of competition in the pharmaceuticals industry. ATMs include engineered cell therapies that reprogram cells to fight disease, gene therapies that involve replacing or editing dysfunctional genes, and nucleic acid therapies that promote or shut down production of a protein.
The life sciences industry is undergoing a fundamental evolution in how drugs are discovered, developed, and manufactured. The industry is shifting from traditional drug research and development techniques used for small molecules and antibodies to, a category that encompasses engineered cell therapies that reprogram cells to fight disease, gene therapies that involve replacing or editing dysfunctional genes, and nucleic acid therapies that promote or shut down production of a protein .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A New Generation of Drug Therapies Requires New Business StrategiesThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
Read more »
A New Generation of Drug Therapies Requires New Business StrategiesThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
Read more »
A New Generation of Drug Therapies Requires New Business StrategiesThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
Read more »
Boomer blames his generation for Gen Z's lazy work ethic: 'Spoiled by my generation'Today's Video Headlines: 10/14/24
Read more »
Key Tips for Integrating New Ulcerative Colitis TherapiesDr Jordan Axelrad discusses practical considerations for adding novel, targeted therapies in ulcerative colitis management.
Read more »
Is Europe Set Up for Equitable Access to Cancer Drugs?Approval, reimbursement, and other factors make access to new cancer therapies complex.
Read more »